The prevention and treatment of metabolic syndrome and high-risk obesity

Current Opinion in Cardiology

Volumn 21, Issue 5, 2006, Pages 479-485

  Molavi, Behzad ^a   Rasouli, Neda ^b   Kern, Philip A ^b  

^a CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

^b NONE

Author keywords

High risk obesity; Lipid; Metabolic syndrome; Prevention; Treatment

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPOCYTOKINE; ADIPONECTIN; ANTIDEPRESSANT AGENT; CANNABINOID 1 RECEPTOR; CYTOKINE; INSULIN; PIOGLITAZONE; PLACEBO; RIMONABANT; ROSIGLITAZONE; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

ADIPOSE TISSUE; ANTIINFLAMMATORY ACTIVITY; BODY FAT DISTRIBUTION; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIET THERAPY; DISEASE ASSOCIATION; FECES INCONTINENCE; FLATULENCE; GASTROINTESTINAL SYMPTOM; GLUCOSE METABOLISM; HEART LEFT VENTRICLE OVERLOAD; HEART VENTRICLE HYPERTROPHY; HIGH RISK PATIENT; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; ISCHEMIC HEART DISEASE; LIFESTYLE; LIPID METABOLISM; LIPID STORAGE; LIVER TOXICITY; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN DIET; PROTEIN SECRETION; REVIEW; RISK ASSESSMENT; RISK FACTOR; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE; WEIGHT GAIN;

ADIPOSE TISSUE; ANTI-OBESITY AGENTS; CARDIOVASCULAR DISEASES; DIET, CARBOHYDRATE-RESTRICTED; HUMANS; LIFE STYLE; LIPID METABOLISM; METABOLIC SYNDROME X; OBESITY, MORBID; RISK FACTORS;

EID: 33747071746     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hco.0000240586.76344.f5     Document Type: Review

References (68)

1. Finkelstein EA, Fiebelkorn IC, Wang G. National medical spending attributable to overweight and obesity: how much, and who's paying? Health Affairs 2003; W3:219-226.
2. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003; 289:76-79.
3. Ogden CL, Carroll MD, Curtin LR, et al. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006; 295:1549-1555.
4. Kissebah AH, Freedman DS, Peiris AN. Health risks of obesity. Med Clin North Am 1989; 73:111-138.
5. Bray GA. Medical consequences of obesity. J Clin Endocrinol Metab 2004; 89:2583-2589.
6. Kissebah AH. Insulin resistance in visceral obesity. Int J Obes 1991; 15 (suppl 2):109-115.
7. Klein S. The case of visceral fat: argument for the defense. J Clin Invest 2004; 113:1530-1532.
8. Mego PA, Molavi B, Lozano P, et al. Quantitative angiographic assessment of blood flow in patients with metabolic syndrome and diabetes with normal or near-normal coronaries [abstract]. Circulation 2004; 110:1876.
9. Liu KH, Chan YL, Chan WB, et al. Mesenteric fat thickness is an independent determinant of metabolic syndrome and identifies subjects with increased carotid intima-media thickness. Diabetes Care 2006; 29:379-384.
10. Kobayashi H, Nakamura T, Miyaoka K, et al. Visceral fat accumulation contributes to insulin resistance, small-sized low-density lipoprotein, and progression of coronary artery disease in middle-aged non-obese Japanese men. Jpn Circ J 2001; 65:193-199.
11. Park SH, Shim KW. Reduction in visceral adiposity is highly related to improvement in vascular endothelial dysfunction among obese women: an assessment of endothelial function by radial artery pulse wave analysis. Yonsei Med J 2005; 46:511-518.
12. Klein S, Fontana L, Young VL, et al. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N Engl J Med 2004; 350:2549-2557.
13. DeFronzo RA, Jacot E, Jequier E, et al. The effect of insulin on the disposal of intravenous glucose. Results from indirect calorimetry and hepatic and femoral venous catheterization. Diabetes 1981; 30:100-107.
14. Lithell H, Lindgarde F, Hellsing K, et al. Body weight, skeletal muscle morphology and enzyme activities in relation to fasting serum insulin concentration and glucose tolerance in 48 year old men. Diabetes 1981; 30:19-25.
15. Lillioja S, Young AA, Culter CL, et al. Skeletal muscle capillary density and fiber type are possible determinants of in vivo insulin resistance in man. J Clin Invest 1987; 80:415-424.
16. Petersen KF, Dufour S, Befroy D, et al. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 2004; 350:664-671.
17. Kern PA, Simsolo RB, Fournier M. Effect of weight loss on muscle fiber type, fiber size, capillarity, and succinate dehydrogenase activity in humans. J Clin Endocrinol Metab 1999; 84:4185-4190.
18. Rasouli N, Raue U, Miles LM, et al. Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue. Am J Physiol Endocrinol Metab 2005; 288:E930-E934. This study demonstrated the simultaneous reduction of intramyocellular lipid, and increases in subcutaneous adipose tissue and insulin sensitivity following thiazolidinedione treatment in humans. Similar mechanisms may prevent lipotoxicity of other organs.
19. Miyazaki Y, Mahankali A, Matsuda M, et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002; 87:2784-2791.
20. DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care 1992; 15:318-368.
21. Bergman R. Toward physiological understanding of glucose tolerance: minimal model approach. Diabetes 1989; 39:1512-1527.
22. Kahn SE, Prigeon RL, McCulloch DK, et al. Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function. Diabetes 1993; 42:1663-1672.
23. Gerich JE. The genetic basis of type 2 diabetes mellitus: impaired insulin secretion versus impaired insulin sensitivity. Endocr Rev 1998; 19:491-503.
24. Dewald O, Sharma S, Adrogue J, et al. Downregulation of peroxisome proliferator-activated receptor-alpha gene expression in a mouse model of ischemic cardiomyopathy is dependent on reactive oxygen species and prevents lipotoxicity. Circulation 2005; 112:407-415.
25. Yagyu H, Chen G, Yokoyama M, et al. Lipoprotein lipase (LpL) on the surface of cardiomyocytes increases lipid uptake and produces a cardiomyopathy. J Clin Invest 2003; 111:419-426.
26. Chiu HC, Kovacs A, Ford DA, et al. A novel mouse model of lipotoxic cardiomyopathy. J Clin Invest 2001; 107:813-822.
27. Zhou YT, Grayburn P, Karim A, et al. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci USA 2000; 97:1784-1789.
28. Ilercil A, Devereux RB, Roman MJ, et al. Relationship of impaired glucose tolerance to left ventricular structure and function: the Strong Heart Study. Am Heart J 2001; 141:992-998.
29. Rutter MK, Parise H, Benjamin EJ, et al. Impact of glucose intolerance and insulin resistance on cardiac structure and function: sex-related differences in the Framingham Heart Study. Circulation 2003; 107:448-454.
30. Sharma S, Adrogue JV, Golfman L, et al. Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J 2004; 18:1692-1700.
31. Lucas AR, Korol R, Pepine CJ. Inflammation in atherosclerosis: some thoughts about acute coronary syndromes. Circulation 2006; 113:e728-e732.
32. Armstrong EJ, Morrow DA, Sabatine MS. Inflammatory biomarkers in acute coronary syndromes: part I: introduction and cytokines. Circulation 2006; 113:e72-e75.
33. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science 1993; 259:87-91.
34. Hotamisligil GS, Arner P, Caro JF, et al. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995; 95:2409-2415.
35. Kern PA, Saghizadeh M, Ong JM, et al. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 1995; 95:2111-2119.
36. Kern PA, Ranganathan S, Li C, et al. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity-associated insulin resistance. Am J Physiol Endocrinol Metab 2001; 280:E745-E751.
37. Mohamed-Ali V, Goodrick S, Rawesh A, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-a, in vivo. J Clin Endocrinol Metab 1997; 82:4196-4200.
38. Bastard JP, Jardel C, Bruckert E, et al. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab 2000; 85:3338-3342.
39. Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM. Tumor necrosis factor α inhibits signaling from the insulin receptor. Proc Natl Acad Sci USA 1994; 91:4854-4858.
40. Patton JS, Shepard HM, Wilking H, et al. Interferons and tumor necrosis factors have similar catabolic effects on 3T3-L1 cells. Proc Natl Acad Sci USA 1986; 83:8313-8317.
41. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997; 389:610-614.
42. Scherer PE, Williams S, Fogliano M, et al. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995; 270:26746-26749.
43. Kumada M, Kihara S, Sumitsuji S, et al., for the Osaka CAD Study Group. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003; 23:85-89.
44. Pajvani UB, Du X, Combs TP, et al. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin Implications fpr metabolic regulation and bioactivity. J Biol Chem 2003; 278:9073-9085.
45. Maeda N, Shimomura I, Kishida K, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002; 8:731-737.
46. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20:1595-1599.
47. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257:79-83.
48. Kern PA, Di Gregorio GB, Lu T, et al. Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-α expression. Diabetes 2003; 52:1779-1785.
49. Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003; 112:1821-1830.
50. Weisberg SP, McCann D, Desai M, et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 1796-1808.
51. Wellen KE, Hotamisligil GS. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 2003; 112:1785-1788.
52. Di Gregorio GB, Yao-Borengasser A, Rasouli N, et al. Expression of CD68 and macrophage chemoattractant protein-1 genes in human adipose and muscle tissues: association with cytokine expression, insulin resistance, and reduction by pioglitazone. Diabetes 2005; 54:2305-2313. This paper demonstrated that human adipose tissue contains macrophages, and that the expression of TNFα and interleukin-6 correlated with adipose macrophages. In response to thiazolidinediones, macrophage number decreased, as did the adipose tissue expression of MCP-1.
53. Consoli A, Devangelio E. Thiazolidinediones and inflammation. Lupus 2005; 14:794-797.
54. Staels B, Fruchart JC. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 2005; 54:2460-2470.
55. Bouskila M, Pajvani UB, Scherer PE. Adiponectin: a relevant player in PPARgamma-agonist-mediated improvements in hepatic insulin sensitivity? Int J Obes (Lond) 2005; 29 (suppl 1):S17-S23.
56. Pajvani UB, Hawkins M, Combs TP, et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 2004; 279:12152-12162.
57. Rasouli N, Yao-Borengasser A, Miles LM, et al. Increased plasma adiponectin in response to pioglitazone does not result from increased gene expression. Am J Physiol Endocrinol Metab 2006; 290:E42-E46.
58. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366:1279-1289.
59. Mykkänen L, Kuusisto J, Haffner SM, et al. Hyperinsulinemia predicts multiple atherogenic changes in lipoproteins in elderly subjects. Arterioscler Thromb 1994; 14:518-526.
60. Friedman JM. A war on obesity, not the obese. Science 2003; 299:856-858.
61. Black SC. Cannabinoid receptor antagonists and obesity. Curr Opin Invest Drugs 2004; 5:389-394.
62. Filippatos TD, Kiortsis DN, Liberopoulos EN, et al. A review of the metabolic effects of sibutramine. Curr Med Res Opin 2005; 21:457-468.
63. Kim SH, Lee YM, Jee SH, Nam CM. Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials. Obes Res 2003; 11:1116-1123.
64. O'Meara S, Riemsma R, Shirran L, et al. A systematic review of the clinical effectiveness of orlistat used for the management of obesity. Obes Rev 2004; 5:51-68.
65. Colombo G, Agabio R, Diaz G, et al. Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci 1998; 63:L113-L117.
66. Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006; 295:761-775.
67. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353:2121-2134.
68. Van Gaal LF, Rissanen AM, Scheen AJ, et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365:1389-1397.